Please use this identifier to cite or link to this item:
Title: Population pharmacokinetics of teicoplanin in children.
Authors: Ramos-Martín, V
Paulus, S
Siner, S
Scott, E
Padmore, K
Newland, P
Drew, R J
Felton, T W
Docobo-Pérez, F
Pizer, B
Pea, F
Peak, M
Turner, M A
Beresford, M W
Hope, W W
metadata.dc.contributor.authoraffiliation: [Ramos-Martín,V; Pizer,B; Turner,MA; Beresford,MW; Hope,WW] Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. [Ramos-Martín,V; Hope,WW] Molecular and Clinical Pharmacology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. [Paulus,S; Siner,S; Scott,E; Padmore,K; Drew,RJ; Pizer,B; Peak,M; Beresford,MW] Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom. [Felton,TW] Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom. [Docobo-Pérez,F] Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain. [Pea,F] nstitute of Clinical Pharmacology, Azienda Ospedaliero-Universitaria Santa Maria della Misericordia; Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy. [Turner,MA] Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom.
Keywords: Staphylococcus aureus resistente a meticilina;Método de Montecarlo;Pruebas de sensibilidad Microbiana;Infecciones estafilocócicas;Teicoplanina
metadata.dc.subject.mesh: Medical Subject Headings::Named Groups::Persons::Age Groups::Adult
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents
Medical Subject Headings::Named Groups::Persons::Age Groups::Child
Medical Subject Headings::Named Groups::Persons::Age Groups::Child::Child, Preschool
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Imidazoles::Creatinine
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Named Groups::Persons::Age Groups::Infant
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Organisms::Bacteria::Endospore-Forming Bacteria::Gram-Positive Endospore-Forming Bacteria::Gram-Positive Endospore-Forming Rods::Staphylococcaceae::Staphylococcus::Staphylococcus aureus::Methicillin-Resistant Staphylococcus aureus
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Microbiological Techniques::Microbial Sensitivity Tests
Medical Subject Headings::Information Science::Information Science::Systems Analysis::Operations Research::Monte Carlo Method
Medical Subject Headings::Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Staphylococcal Infections
Medical Subject Headings::Chemicals and Drugs::Carbohydrates::Glycoconjugates::Glycopeptides::Teicoplanin
Medical Subject Headings::Named Groups::Persons::Age Groups::Adolescent
Issue Date: Nov-2014
Publisher: American Society for Microbiology
Citation: Ramos-Martín V, Paulus S, Siner S, Scott E, Padmore K, Newland P, et al. Population pharmacokinetics of teicoplanin in children. Antimicrob. Agents Chemother. 2014; 58(11):6920-7
Abstract: Teicoplanin is frequently administered to treat Gram-positive infections in pediatric patients. However, not enough is known about the pharmacokinetics (PK) of teicoplanin in children to justify the optimal dosing regimen. The aim of this study was to determine the population PK of teicoplanin in children and evaluate the current dosage regimens. A PK hospital-based study was conducted. Current dosage recommendations were used for children up to 16 years of age. Thirty-nine children were recruited. Serum samples were collected at the first dose interval (1, 3, 6, and 24 h) and at steady state. A standard 2-compartment PK model was developed, followed by structural models that incorporated weight. Weight was allowed to affect clearance (CL) using linear and allometric scaling terms. The linear model best accounted for the observed data and was subsequently chosen for Monte Carlo simulations. The PK parameter medians/means (standard deviation [SD]) were as follows: CL, [0.019/0.023 (0.01)] × weight liters/h/kg of body weight; volume, 2.282/4.138 liters (4.14 liters); first-order rate constant from the central to peripheral compartment (Kcp), 0.474/3.876 h(-1) (8.16 h(-1)); and first-order rate constant from peripheral to central compartment (Kpc), 0.292/3.994 h(-1) (8.93 h(-1)). The percentage of patients with a minimum concentration of drug in serum (Cmin) of <10 mg/liter was 53.85%. The median/mean (SD) total population area under the concentration-time curve (AUC) was 619/527.05 mg · h/liter (166.03 mg · h/liter). Based on Monte Carlo simulations, only 30.04% (median AUC, 507.04 mg · h/liter), 44.88% (494.1 mg · h/liter), and 60.54% (452.03 mg · h/liter) of patients weighing 50, 25, and 10 kg, respectively, attained trough concentrations of >10 mg/liter by day 4 of treatment. The teicoplanin population PK is highly variable in children, with a wider AUC distribution spread than for adults. Therapeutic drug monitoring should be a routine requirement to minimize suboptimal concentrations. (This trial has been registered in the European Clinical Trials Database Registry [EudraCT] under registration number 2012-005738-12.).
Description: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't. This trial has been registered in the European Clinical Trials Database Registry [EudraCT] under registration number 2012-005738-12.
metadata.dc.identifier.doi: 10.1128/AAC.03685-14
ISSN: 1098-6596 (Online)
0066-4804 (Print)
Appears in Collections:01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
Ramos_PopulationPharmacokinetics.pdfArtículo publicado980,08 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons